Sort by
Road to Eliminating Out-of-Pocket Payment in Sub-Saharan Africa, Elucidating the Role of Primary Care Health Workforce: A Scoping Review Protocol
Julius Cudjoe
,Wisdom Kwabla Atatsi
,Bernard Kwabena Adjei
,Seyram Gockel Ashong
Posted: 15 May 2026
Effects of Virtual Human–Based Oral Health Education on Adolescent Oral Health Literacy and Behaviors: A Cluster Randomised Controlled Trial
Ji-Soo Kim
,Younghee Noh
,Jong-Hwa Jang
Posted: 12 May 2026
Beyond Algorithmic Oversight: Internal Morality of Medicine and Meaningful Human Control in AI-Assisted Care
Aleksej Omeljančiuk
,Eimantas Peičius
,Aušra Urbonienė
,Gvidas Urbonas
Posted: 09 May 2026
Voice Biometric Access Control in Blockchain-Enhanced Electronic Health Records
Prashnatita Pal
,Rituparna Bhattacharya
Posted: 08 May 2026
Islands in an Obesogenic Ocean: A Multiscale Spatial Analysis of School Neighborhood Food Environments in Michigan
Gang Xu
Posted: 08 May 2026
The Role of the Biomanufacturing Industry in Developing Diagnostics and mRNA Vaccines Against COVID-19
Ishfaq Ahmed
,Quendrix Martinez
,Shayne McRae
,Ashwin Dharmalingam
Posted: 07 May 2026
A Time-Bound Clinical Framework for Silver Diamine Fluoride as Interim Stabilization in Severe Early Childhood Caries: Bridging Preservation to Precision with Equity and Accountability
Ziad D. Baghdadi
Posted: 06 May 2026
Nutritional Follow-Up in Indigenous Children Under Five Years in Colombia
Pedro Barrera
,Andrés Felipe Mora-Salamanca
,Kevin Rico
,Sandra Barrera-Ayala
Posted: 05 May 2026
Forecasting Assisted Living Demand in Singapore: Evidence-Based ARIMA Projections to Inform Policy and Practice
Ang Amberyce
,Elijah Loy
Posted: 05 May 2026
Epidemiological Transition and the Crisis of the Treatment Model: The Need for a Shift Toward Preventive and Integrative Healthcare
Alexander Dmitriev
Posted: 01 May 2026
Mapping Cold-Chain Waste in Immunization Programmes Across Waste Streams, Policy Coverage, and Operational Management
Snehil Singh
,Sabin Syed
Posted: 27 April 2026
Social Media Exposure and Dietary Quality in University Restaurant Consumers: A PLS-SEM Approach from Northern Peru
Luis Edgardo Cruz Salinas
,Marco Agustín Arbulú Ballesteros
,Marilú Trinidad Flores Lezama
,Carlos José Sandoval Reyes
Posted: 23 April 2026
Introduction to Overreach: The Deadly Price of Regulatory Surveillance Captured: How Medicine Became an Instrument of State Power
Richard Henry Parrish II
Posted: 22 April 2026
How Partisan Policies Can Shape Health Behaviors: Executive Order Proof-of-Vaccine Mandate Bans Increased COVID-19 Vaccinations
Deena N. Brosi
,Gregory Tung
,Beth Mcmanus
,Srinivas Parinandi
,Glen Mays
Posted: 21 April 2026
Comparative Medico-Legal Frameworks for Psilocybin Regulation: A March 2026 Update
Octavian Victor Brinzei
Posted: 20 April 2026
Who Bears the Highest Costs of Breast Cancer? A Cost-of-Illness Study in Poland from a Societal Perspective
Michał Seweryn
,Agnieszka Leszczyńska
,Małgorzata Budasz-Świderska
,Tomasz Banaś
,Paweł Michał Potocki
Posted: 18 April 2026
Excluded Lives: Migrant Status and Access to Healthcare in South Africa
Alex Asakitikpi
Posted: 17 April 2026
Evaluating the Cost-Effectiveness and Budget Impact of the 20-Valent Pneumococcal Conjugate Vaccine Among Adults in Taiwan
Ya-Min Yang
,Yi-Wei Wang
,Ahuva Averin
,Anu Suokas
,Mark Atwood
,Mary MacKinnon
,Liping Huang
Posted: 15 April 2026
Evolving Health Policies and Pricing Dynamics in U.S. Multiple Sclerosis Therapies: A Longitudinal Analysis with Policy Implications
Serdar Kuzu
,Ali Kablan
,Murat Kirişci
,Zehra Koyuncu
Background and Objectives: Multiple sclerosis (MS) is a chronic autoimmune neuroinflammatory condition associated with significant disability. Given the increasing number of patients with MS, the growing number of available disease-modifying therapies (DMTs), and the substantial economic burden associated with MS, it is critically important to determine which treatment options are the most cost-effective. The economic burden of MS is considerable, and high-cost DMTs, whose prices continue to rise, represent the primary driver of health expenditures related to MS. The primary aim of this narrative review is to provide a brief review of the economic issues related to MS DMTs, including pricing trends, economic burden, and their impact on patient care, and to propose potential policy solutions. Materials and Methods: The aim of the study was to compare the cost effectiveness of The annual costs of DMTs from 1993 to 2023 in USA. An examination of DMT pricing trends suggests that pricing has been influenced in part by within-class competition and the availability of generic DMT options. Results: Over the past decade, the prices of DMTs have increased by more than 50%. Currently, the annual cost of many DMTs used in the treatment of MS has exceeded $100,000, and their economic value is widely debated. The high cost of DMTs and difficulties in timely access to medications can lead to psychological stress among many patients. Studies on cost-effectiveness indicate that the clinical benefits provided by DMTs do not fully justify their high costs, which further exacerbates issues related to economic accessibility. Conclusions: Collaborative neuropsychiatric care models, in which neurologists and mental health professionals work in coordination, may improve symptom recognition, optimize adherence to DMTs, and enhance overall functioning. Given that treatment non-adherence and reduced quality of life negatively affect cost-effectiveness outcomes, early psychiatric intervention may indirectly improve the economic value profile of high-cost DMTs.
Background and Objectives: Multiple sclerosis (MS) is a chronic autoimmune neuroinflammatory condition associated with significant disability. Given the increasing number of patients with MS, the growing number of available disease-modifying therapies (DMTs), and the substantial economic burden associated with MS, it is critically important to determine which treatment options are the most cost-effective. The economic burden of MS is considerable, and high-cost DMTs, whose prices continue to rise, represent the primary driver of health expenditures related to MS. The primary aim of this narrative review is to provide a brief review of the economic issues related to MS DMTs, including pricing trends, economic burden, and their impact on patient care, and to propose potential policy solutions. Materials and Methods: The aim of the study was to compare the cost effectiveness of The annual costs of DMTs from 1993 to 2023 in USA. An examination of DMT pricing trends suggests that pricing has been influenced in part by within-class competition and the availability of generic DMT options. Results: Over the past decade, the prices of DMTs have increased by more than 50%. Currently, the annual cost of many DMTs used in the treatment of MS has exceeded $100,000, and their economic value is widely debated. The high cost of DMTs and difficulties in timely access to medications can lead to psychological stress among many patients. Studies on cost-effectiveness indicate that the clinical benefits provided by DMTs do not fully justify their high costs, which further exacerbates issues related to economic accessibility. Conclusions: Collaborative neuropsychiatric care models, in which neurologists and mental health professionals work in coordination, may improve symptom recognition, optimize adherence to DMTs, and enhance overall functioning. Given that treatment non-adherence and reduced quality of life negatively affect cost-effectiveness outcomes, early psychiatric intervention may indirectly improve the economic value profile of high-cost DMTs.
Posted: 13 April 2026
An Integrated Care Pathway for Pediatric Oral Health: A Multicenter Study on Dental Caries, Malocclusions, and Oral Hygiene in Three Italian Regions
Erika Roncarati
,Dorina Lauritano
,Saverio Ceraulo
,Luigi Baggi
,Roberta Calcaterra
,Roberto Gatto
,Sivia Caruso
,Stefano Cianetti
,Guido Lombardo
,Francesco Carinci
Posted: 13 April 2026
of 29